Clinical and Applied Thrombosis/Hemostasis (Jun 2019)

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

  • Eduardo Ramacciotti MD, PhD,
  • Leandro B. Agati PhD,
  • Roberto Augusto Caffaro MD, PhD,
  • Giuliano G. Volpiani MD,
  • Renato D. Lopes MD, PhD,
  • Anthony J. Comerota MD,
  • Jawed Fareed PhD

DOI
https://doi.org/10.1177/1076029619856433
Journal volume & issue
Vol. 25

Abstract

Read online

Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.